Yesterday, July 19, 2016, 36 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $39.90 to $2,023,500.00.

Highlighted Stocks Traded by Insiders:

Guess (GES) - FREE Research Report

Chidoni Anthony, who is Director at Guess, sold 4,000 shares at $15.54 on July 19, 2016. Following this transaction, the Director owned 157,744 shares meaning that the stake was reduced by 2.47% with the 4,000-share transaction.

The shares most recently traded at $14.39, down $1.15, or 7.99% since the insider transaction. Historical insider transactions for Guess go as follows:

  • 4-Week # shares bought: 1,233
  • 4-Week # shares sold: 11,855
  • 12-Week # shares bought: 1,233
  • 12-Week # shares sold: 11,855
  • 24-Week # shares bought: 2,264
  • 24-Week # shares sold: 11,855

The average volume for Guess has been 1.1 million shares per day over the past 30 days. Guess has a market cap of $1.3 billion and is part of the services sector and retail industry. Shares are down 24.31% year-to-date as of the close of trading on Tuesday.

Guess , Inc. designs, markets, distributes, and licenses lifestyle collections of contemporary apparel and accessories for men, women, and children that reflect the American lifestyle and European fashion sensibilities. The stock currently has a dividend yield of 5.85%. The company has a P/E ratio of 24.8. Currently, there is 1 analyst who rates Guess a buy, no analysts rate it a sell, and 7 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on GES - FREE

TheStreet Quant Ratings

rates Guess as a

hold

. Among the primary strengths of the company is its solid financial position based on a variety of debt and liquidity measures that we have evaluated. At the same time, however, we also find weaknesses including a generally disappointing performance in the stock itself, feeble growth in the company's earnings per share and deteriorating net income. Get the full

Guess Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Amphastar Pharmaceuticals (AMPH) - FREE Research Report

Peters William J, who is CFO, SVP & Treasurer at Amphastar Pharmaceuticals, sold 2,297 shares at $17.76 on July 19, 2016. Following this transaction, the CFO, SVP & Treasurer owned 64,652 shares meaning that the stake was reduced by 3.43% with the 2,297-share transaction.

The shares most recently traded at $17.42, down $0.34, or 1.95% since the insider transaction. Historical insider transactions for Amphastar Pharmaceuticals go as follows:

  • 4-Week # shares sold: 1,551
  • 12-Week # shares sold: 19,453
  • 24-Week # shares bought: 6,000
  • 24-Week # shares sold: 23,280

The average volume for Amphastar Pharmaceuticals has been 311,400 shares per day over the past 30 days. Amphastar Pharmaceuticals has a market cap of $782.6 million and is part of the health care sector and drugs industry. Shares are up 19.89% year-to-date as of the close of trading on Tuesday.

Amphastar Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development, manufacture, marketing, and sale of generic and proprietary injectable, inhalation, and intranasal products. The company has a P/E ratio of 1745.0. Currently, there are 5 analysts who rate Amphastar Pharmaceuticals a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on AMPH - FREE

TheStreet Quant Ratings

rates Amphastar Pharmaceuticals as a

hold

. The company's strengths can be seen in multiple areas, such as its impressive record of earnings per share growth, compelling growth in net income and revenue growth. However, as a counter to these strengths, we find that the stock has had a generally disappointing performance in the past year. Get the full

Amphastar Pharmaceuticals Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Analogic (ALOG) - FREE Research Report

Chandra Shalabh, who is Officer at Analogic, sold 1,250 shares at $81.82 on July 19, 2016. Following this transaction, the Officer owned 4,567 shares meaning that the stake was reduced by 21.49% with the 1,250-share transaction.

The shares most recently traded at $81.86, up $0.04, or 0.05% since the insider transaction. Historical insider transactions for Analogic go as follows:

  • 4-Week # shares sold: 2,397
  • 12-Week # shares sold: 7,147
  • 24-Week # shares sold: 7,647

The average volume for Analogic has been 69,100 shares per day over the past 30 days. Analogic has a market cap of $1.0 billion and is part of the health care sector and health services industry. Shares are down 1.34% year-to-date as of the close of trading on Tuesday.

Analogic Corporation, a technology company, designs, manufactures, and sells medical imaging, ultrasound, and security systems and subsystems to original equipment manufacturers (OEMs) and end users in the healthcare and airport security markets worldwide. The stock currently has a dividend yield of 0.48%. The company has a P/E ratio of 72.5. Currently, there is 1 analyst who rates Analogic a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on ALOG - FREE

TheStreet Quant Ratings

rates Analogic as a

buy

. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, good cash flow from operations, expanding profit margins and solid stock price performance. We feel its strengths outweigh the fact that the company has had sub par growth in net income. Get the full

Analogic Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.